Archives

Aptahem AB (publ), announce today that the Chairman of the Board of Directors, Kjell G Stenberg, has requested his own resignation from the Board. Due to this, the Board of Directors will call [...]

Aptahem AB, a leading developer of aptamer-based drugs, announced today that the company is now starting large-scale manufacturing after LGC Bioresearch Technologies Inc. (LGC) completed the [...]

BioStock published an article on 10 July 2020 about Aptahem, which can be read in full below. Last night, Malmö-based Aptahem announced that they have entered a preclinical collaboration with the [...]

Aptahem (publ) today announced the beginning of a collaboration with the University Health Network, a research hospital affiliated with University of Toronto in Canada. The collaboration aims to [...]

BioStock published an article on 1 July 2020 about Aptahem, which can be read in full below. At the end of last year, Aptahem entered a consortium with Örebro University with the aim of [...]

Aptahem (publ) is a biotech company developing aptamer-based pharmaceuticals for the treatment of life-threatening conditions, such as sepsis. A similar mechanism occurs in cardiovascular [...]

BioStock published an article on 24 June 2020 about Aptahem, which can be read in full below. For half a century Dexamethasone has been used to treat diseases such as rheumatoid arthritis and [...]

Aptahem today informs that the company’s latest patent application has been registered in several countries and are subject to approval. The patent application, which is an international PCT [...]

BioStock published an article on 29 April 2020 about Aptahem, which can be read in full below. Aptahem, whose primary drug candidate Apta-1 is being developed as an acute treatment for sepsis, [...]

Aptahem today announced that the company is expanding its team with Suzanne Kilany as Clinical Research Director for the next step in the development of the company’s lead drug candidate, Apta-1. [...]